Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22950788 | 1.00 | AKR1B1 (0.44) | AKR1B1LTB4R | |
| SCHEMBL1106771 | 0.80 | AKR1B1 (0.48) | AKR1B1 | |
| SCHEMBL14502205 | 0.77 | AKR1B1 (0.43) | AKR1B1 | |
| SCHEMBL23871106 | 0.77 | AKR1B1 (0.43) | AKR1B1 | |
| SCHEMBL23158365 | 0.76 | AKR1B1 (0.35) | AKR1B1 | |
| SCHEMBL24658619 | 0.76 | AKR1B1 (0.33) | AKR1B1 | |
| SCHEMBL23733926 | 0.72 | AKR1B1 (0.38) | AKR1B1 | |
| SCHEMBL22951183 | 0.72 | AKR1B1 (0.32) | AKR1B1 | |
| SCHEMBL2737007 | 0.71 | LTB4R (0.34) | AKR1B1LTB4R | |
| SCHEMBL5705245 | 0.71 | AKR1B1 (0.32) | AKR1B1LTB4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402851-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | ESPERVITA THERAPEUTICS, INC. | 2022-12-22 | — | — | US | disclosed |
| US-11084773-B1 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and their use for the prevention or treatment of disease | ESPERVITA THERAPEUTICS, INC. (US) | 2021-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11084773-B1 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and their use for the prevention or treatment of disease | CPT1A, PPARG, PC | AKR1B1 154/4885LTB4R 1150/4885 |
| US-20220402851-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | CPT1A, PPARG, PC | AKR1B1 156/4885LTB4R 1146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.